- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
12
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
12 companies
Sotera Health
Market Cap: US$4.8b
Provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$16.84
7D
-3.4%
1Y
29.8%
BioLife Solutions
Market Cap: US$1.2b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$25.51
7D
-4.4%
1Y
1.3%
AbbVie
Market Cap: US$396.5b
A research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
ABBV
US$230.24
7D
1.1%
1Y
30.5%
Caris Life Sciences
Market Cap: US$7.4b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$27.24
7D
8.6%
1Y
n/a
Neurocrine Biosciences
Market Cap: US$15.2b
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
NBIX
US$151.96
7D
0.3%
1Y
20.2%
Avadel Pharmaceuticals
Market Cap: US$2.1b
Operates as a biopharmaceutical company in the United States.
AVDL
US$21.36
7D
-0.2%
1Y
114.5%
Rhythm Pharmaceuticals
Market Cap: US$6.8b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$104.63
7D
-2.6%
1Y
73.3%
Ligand Pharmaceuticals
Market Cap: US$3.8b
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
LGND
US$193.03
7D
-6.4%
1Y
56.3%
Protagonist Therapeutics
Market Cap: US$5.4b
A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
PTGX
US$86.07
7D
-4.4%
1Y
106.5%
Alnylam Pharmaceuticals
Market Cap: US$62.5b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$473.29
7D
6.3%
1Y
88.0%
Eli Lilly
Market Cap: US$936.7b
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
LLY
US$1,033.56
7D
-6.4%
1Y
24.5%
Exact Sciences
Market Cap: US$19.2b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS
US$101.25
7D
-0.2%
1Y
57.9%